Novartis plans to restructure its U.S. operations. According to a company email sent to employees by David Epstein, head of Novartis Pharmaceuticals, the restructuring is in response to a changing environment and is an effort to innovate the company’s product portfolio over the next several years. According to the email, four new business units will be created, Primary Care, Multiple Sclerosis, Psychiatry/Neuroscience and Respiratory/Transplant/Infectious Disease. The changes take effect May 1 a...